1
Orphan Designations
0 approved, 1 designated
0
FDA Approvals
0
Active Trials
3
Rare Diseases
across 4 areas
0
News (30d)
Quiet
Sesen Bio, Inc. (Sesen Bio) is a company with 1 orphan drug designation across 3 rare diseases. gene therapy candidates in 1 disease.
Disease-by-disease pipeline progression from orphan designation through clinical trials to FDA approval.
Source: FDA Orphan Drug Designations, ClinicalTrials.gov, Drugs@FDA
| Disease | Drug(s) | Stage |
|---|---|---|
| Lynch syndrome | recombinant fusion protein with a truncated form of the cytotoxic protein Pseudomonas exotoxin | Des.TrialAppr. |
| Lynch syndrome 8 | recombinant fusion protein with a truncated form of the cytotoxic protein Pseudomonas exotoxin | Des.TrialAppr. |
| congenital diarrhea 5 with tufting enteropathy | recombinant fusion protein with a truncated form of the cytotoxic protein Pseudomonas exotoxin | Des.TrialAppr. |
0% of portfolio targets high unmet need diseases
0
overlap in 2+ diseases
1/3
candidate diseases
0
avg importance: 0
0
affecting portfolio
0% of portfolio targets high unmet need diseases
0
overlap in 2+ diseases
1/3
candidate diseases
0
avg importance: 0
0
affecting portfolio